Item Details
Eli Radiopharma raises $60m to accelerate cancer and neurological treatments
Chinese biotechnology company Eli Radiopharma has raised approximately $60m in Series A funding led by Huagai Capital and Bayland Capital. The investment will support the development of radiopharmaceutical treatments for cancer and neurological diseases, including preclinical research and early clinical development. HPC could introduce pharmaceutical manufacturers, clinical research organisations, specialist laboratories, medical equipment suppliers and international healthcare investors interested in China's growing biotechnology market.
Get in Touch
We’ll get back to you shortly.